XMD17-109_1435488-37-1_CoA_MedChemExpress
血清转铁蛋白、尿液转铁蛋白、尿液视黄醇结合蛋白、胱抑素C_检测对糖尿病肾病的临床应用价值分析
DOI：10.16658/ki.1672-4062.2023.04.025血清转铁蛋白、尿液转铁蛋白、尿液视黄醇结合蛋白、胱抑素C检测对糖尿病肾病的临床应用价值分析袁金，陈琼，张雯福州市第八医院检验科，福建福州350000[摘要]目的分析血清转铁蛋白、尿液转铁蛋白、尿液视黄醇结合蛋白联合胱抑素C检测对糖尿病肾病诊断的应用价值。
方法选取2019年1月—2022年2月福州市第八医院治疗的60例糖尿病肾病患者为研究对象，依据患者的尿白蛋白排泄量/肌酐比值差异将其分为A组（22例，蛋白尿正常）、B组（21例，微量蛋白尿）、C 组（17例，大量蛋白尿），另选同期的20名体检健康者设为对照组。
所有患者均接受血清转铁蛋白、尿液转铁蛋白、尿液视黄醇结合蛋白联合胱抑素C检测，分析4组检测结果。
结果4组受检者血清转铁蛋白、尿液转铁蛋白、尿液视黄醇结合蛋白、胱抑素C检测结果比较，差异有统计学意义（F=538.653、10.125、197.153、416.223，P<0.05）。
结论血清转铁蛋白、尿液转铁蛋白、尿液视黄醇结合蛋白、胱抑素C检测对于糖尿病肾病患者有一定的参考价值。
[关键词] 血清转铁蛋白；尿液转铁蛋白；尿液视黄醇结合蛋白；胱抑素C；糖尿病肾病[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）02（b）-0025-04Analysis of Serum Transferrin, Urine Transferrin, Urine Retinol-binding Protein, Cystatin C Clinical Application Value of Diabetes NephropathyYUAN Jin, CHEN Qiong, ZHANG WenDepartment of Clinical Laboratory, Fuzhou Eighth Hospital, Fuzhou, Fujian Province, 350000 China[Abstract] Objective To analyze the diagnostic value of serum transferrin, urine transferrin, urine retinol-binding protein combined with cystatin C in diabetic nephropathy. Methods 60 patients with diabetes nephropathy who were treated in Fuzhou Eighth Hospital from January 2019 to February 2022 were selected as the study subjects. According to the difference of urinary albumin excretion/creatinine ratio, the patients were divided into group A (22 cases, nor⁃mal proteinuria), group B (21 cases, microalbuminuria), and group C (17 cases, massive proteinuria), another 20 healthy individuals who underwent physical examination during the same period were selected as the control group. All patients received serum transferrin, urine transferrin, urine retinol-binding protein combined with cystatin C detec⁃tion. The test results were analyzed between the four groups. Results In the detection results of serum transferrin, urine transferrin, urine retinol binding protein, and cystatin C among the four groups of subjects, the difference was statistically significant (F=538.653, 10.125, 197.153, 416.223, P<0.05). Conclusion The detection of serum transfer⁃rin, urine transferrin, urinary retinol binding protein and cystatin C has certain reference value for patients with diabe⁃tes nephropathy.[Key words] Serum transferrin; Urine transferrin; Urine retinol-binding protein; Cystatin C; Diabetic nephropathy糖尿病肾病若未能及时诊治，一旦发展至终末期治疗的难度会显著提高[1]。
3_种常用碳青霉烯类抗生素血药浓度UPLC-MS
3种常用碳青霉烯类抗生素血药浓度UPLC-MS/MS检测方法的建立Δ秦怡1＊，张瑞霞2，吕雅瑶2，翁莉莉1，张弋2 #（1.天津医科大学一中心临床学院，天津 300192；2.天津市第一中心医院药学部，天津 300192）中图分类号 R917；R978.1文献标志码 A 文章编号 1001-0408（2024）03-0343-05DOI 10.6039/j.issn.1001-0408.2024.03.14摘要目的建立3种临床常用碳青霉烯类抗生素——厄他培南（ETP）、亚胺培南（IPM）、美罗培南（MEM）血药浓度检测的超高效液相色谱-质谱联用（UPLC-MS/MS）法。
方法血浆样品经甲醇沉淀蛋白后，以3种抗生素的稳定性同位素（ETP-D4、IPM-D4、MEM-D6）为内标，采用ACQUITY UPLC BEH C18（2.1 mm×50 mm，1.7μm）色谱柱分离；流动相为98%乙腈+2%水+0.1%甲酸和98%水+2%乙腈+0.1%甲酸，梯度洗脱；流速为0.3 mL/min；柱温为40 ℃；采用正离子、多反应监测模式进行扫描分析。
结果该方法专属性良好，在ETP、IPM、MEM 0.2～200、0.1～100、0.1～100μg/mL范围内线性良好（r2≥0.993），批内、批间精密度和准确度良好（RE均≤5.14%，RSD均≤11.15%），基质效应、提取回收率较一致（RSD≤12.99%）。
结论本实验建立了一种可以同时定量ETP、IPM、MEM血药浓度的UPLC-MS/MS法，该方法样品前处理简单、检测时间短、所需样品量少，可满足临床需求。
关键词碳青霉烯类抗生素；超高效液相色谱-质谱联用；血药浓度；厄他培南；亚胺培南；美罗培南Establishment of UPLC-MS/MS method for the determination of plasma concentration of three common carbapenem antibioticsQIN Yi1，ZHANG Ruixia2，LYU Yayao2，WENG Lili1，ZHANG Yi2（1. First Central Clinical College of Tianjin Medical University，Tianjin 300192，China；2. Dept. of Pharmacy，Tianjin First Central Clinical Hospital，Tianjin 300192， China）ABSTRACT OBJECTIVE To establish a UPLC-MS/MS method for the determination of plasma concentration of three carbapenem antibiotics，i.e. ertapenem （ETP），imipenem （IPM）and meropenem （MEM）.METHODS After protein precipitation with methanol，the plasma samples were separated by ACQUITY UPLC BEH C18column （2.1mm×50mm，1.7μm）using stable isotopes of three antibiotics （ETP-D4，IPM-D4，MEM-D6）as the internal standard. The mobile phases were 98%acetonitrile +2% water +0.1%formic acid and 98%water +2%acetonitrile +0.1%formic acid，by gradient elution. The flow rate was 0.3mL/min and the column temperature was 40 ℃. Scanning analysis was performed in the positive ion and multiple reaction monitoring mode. RESULTS The method had good specificity，good linearity （r2≥0.993）in the range of 0.2-200，0.1-100and 0.1-100μg/mL of ETP，IPM and MEM，and good intra-batch and inter-batch precision and accuracy （all RE≤5.14%，all RSD≤11.15%），the matrix effect and extraction recovery were consistent （RSD≤12.99%）. CONCLUSIONS This study establishes the UPLC-MS/MS method to simultaneously quantify the plasma concentration of ETP，IPM and MEM. The method has the advantages of simple pretreatment， short detection time and small sample quantity to meet clinical requirement.KEYWORDS carbapenem antibiotics； UPLC-MS/MS； plasma concentration； ertapenem； imipenem； meropenem碳青霉烯类抗生素具有抗菌谱广、抗菌活性强、耐药率低的特点，已成为治疗重症感染的主要选择。
CFDA SE (细胞增殖示踪荧光探针) 说明书
CFDA SE (细胞增殖示踪荧光探针) 产品编号产品名称包装C1031 CFDA SE (细胞增殖示踪荧光探针) 5mg产品简介：CFDA SE 的全称为Carboxyfluorescein diacetate, succinimidyl ester ，是一种近年来被广泛应用的细胞增殖检测用荧光探针，也可以用于细胞的荧光示踪。
基于CFDA SE 荧光标记的细胞增殖检测和[3H]-thymidine 掺入、BrdU 标记获得的检测结果完全一致，但同时可以提供更多的细胞增殖信息。
使用CFDA SE 检测可以提供整个细胞群中有多少比例的细胞分裂了1次、2次或更多次数，同时如果和其它荧光探针联用，可以获取不同分裂次数细胞的其它相关信息。
CFDA-SE 的分子式为C 29H 19NO 11，分子量为557.47，CAS number 为150347-59-4。
CFDA SE 可以通透细胞膜，进入细胞后可以被细胞内的酯酶(esterase)催化分解成CFSE ，CFSE 可以偶发性地(spontaneously)并不可逆地和细胞内蛋白的Lysine 残基或其它氨基发生结合反应，并标记这些蛋白。
在加入荧光探针CFDA SE 后大约24小时，即可充分标记细胞。
被CFDA SE 标记的非分裂细胞的荧光非常稳定，稳定标记的时间可达数个月。
CFDA SE 标记细胞的荧光非常均一，比以前使用的其它细胞示踪荧光探针例如PKH26的荧光更加均一，并且分裂后的子代细胞的荧光分配也更均匀。
由于CFDA SE 标记细胞的荧光非常均匀和稳定，每分裂一次子代细胞的荧光会减弱一半，这样通过流式细胞仪检测就可以检测出没有分裂的细胞，分裂一次的细胞(1/2的荧光强度)，分离两次的细胞(1/4的荧光强度)，分裂三次的细胞(1/8的荧光强度)以及类似的其它分裂次数的细胞。
采用CFDA SE 通过流式细胞仪检测获得的检测结果参考右图。
每一个峰代表一种分裂次数的细胞，从右至左的峰通常依次为分裂0次、1次、2次、3次等次数的细胞。
Lacosamide_175481-36-4_MSDS_MedChemExpress
MSDS1 Composition7 Accident Release MeasureProduct Name:LacosamideChemical Name:PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavyrubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area andwash spill site after material pickup is complete.Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-,(2R)-CAS No.:175481-36-48 Accident Release MeasureAppearance:White to off-white(Solid)Formula:C13H18N2O39 Toxicological InformationSolubility:To the best of our knowledge, the chemical, physical, andtoxicological properties have not been thoroughly investigated.No data available.p p p p DMSO ≥48mg/mL Water ≥24mg/mL Ethanol ≥48mg/mL2 Handling and Storage10 Regulary Information3 Stability and Reactivity11Disposal ConsiderationsCLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Store in a properly sealed container store at -20℃,shelflife is 2 years.11 Disposal Considerations 4 Hazards Identification12 Transport Information5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.As specific country, federal, state and local environmentalregulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.5 First Aid13 Other InformationThe above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d tINHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin withsoap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes withcopious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.6 Fire Fighting Measureshandling or from contact with the above product.EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes onlyMedchemexpress LLCto prevent contact with skin and eyes.18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
2_型糖尿病肾病患者血浆D_二聚体水平的检测及临床意义分析
· 医学检验 ·糖尿病新世界 2024年1月糖尿病新世界 DIABETES NEW WORLD2型糖尿病肾病患者血浆D 二聚体水平的检测及临床意义分析陈君颖，游含宇，叶玉琼厦门市中医院检验科，福建厦门 361009[摘要] 目的 评估血浆D 二聚体水平的检测应用在2型糖尿病肾病患者中的作用和临床意义。
方法 回顾性分析厦门市中医院在2021年1月—2022年1月期间收治的120例2型糖尿病肾病患者的全部病历资料，按照尿微量白蛋白排泄率（Urinary Albumin Ejection Rate ， UACR ）予以分组，分为正常蛋白尿组（n =40，UACR<20 μg/min ）、微量蛋白尿组（n =40，UACR 在20~200 μg/min 之间）、大量尿蛋白组（n =40，UACR>200 μg/min ），每组40例。
选取同期健康体检者40例作为对照组，全部均接受血浆D 二聚体水平检查，分析效果与临床意义。
结果 大量尿蛋白组的D 二聚体高于微量蛋白尿组、正常蛋白尿组、对照组，且4组D 二聚体水平对比，差异有统计学意义（P 均<0.05）。
血浆D 二聚体与2型糖尿病肾病患者蛋白尿水平呈正相关（r =0.253）。
结论 2型糖尿病肾病患者蛋白尿水平越高，血浆D 二聚体水平越高，血浆D 二聚体可以作为检测糖尿病肾病患者疾病进展的重要参考指标。
[关键词] 血浆D 二聚体水平；2型糖尿病肾病；临床意义[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2024）01（b ）-0052-04Detection and Clinical Significance of Plasma D-dimer Level in Patients with Type 2 Diabetic NephropathyCHEN Junying, YOU Hanyu, YE YuqiongDepartment of Laboratory, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian Province, 361009 China [Abstract ] Objective To evaluate the role and clinical significance of plasma D-dimer level detection in patients with type 2 diabetic nephropathy. Methods All the medical records of 120 patients with type 2 diabetic nephropathy admitted to Xiamen Hospital of Traditional Chinese Medicine from January 2021 to January 2022 were retrospectively analyzed. According to the urinary albumin ejection rate (UACR), the patients were divided into normal albuminuria group (n =40, UACR<20 μg/min), microalbuminuria group (n =40, UACR>200 μg/min) and large urinary protein group (n =40, UACR>200 μg/min), with 40 cases in each group. 40 healthy subjects in the same period were selected as the control group, and all of them were examined by plasma D-dimer level to analyze the effect and clinical significance. Results The level of D-dimer in the large urinary protein group was higher than that in the microalbuminuria group, the normal albuminuria group and the control group, and comparison of D-dimer levels in 4 groups the differences were statistically significant (all P <0.05). Plasma D-dimer was positively correlated with albuminuria level in type 2 diabetic nephropathy patients (r =0.253). Conclusion The higher the level of proteinuria in type 2 diabetic nephropa⁃thy patients, the higher the level of plasma D-dimer, which can be used as an important reference index to detect the disease progression in diabetic nephropathy patients.[Key words ] Plasma D-dimer level; Type 2 diabetic nephropathy; Clinical significance糖尿病肾病是一种严重的糖尿病微血管病变，其发病率呈逐年上升趋势[1]。
达格列净联合二甲双胍治疗对2_型糖尿病患者血糖、胰岛敏感性的影响
DOI：10.16658/ki.1672-4062.2024.01.061达格列净联合二甲双胍治疗对2型糖尿病患者血糖、胰岛敏感性的影响郑婷婷1，陈李燊2，饶志辉1，林美玲11.福建医科大学附属龙岩第一医院药剂科，福建龙岩364000；2.厦门大学附属福州第二医院药剂科，福建福州350007[摘要]目的探讨达格列净联合二甲双胍治疗对2型糖尿病（Type 2 Diabetes Mellitus， T2MD）患者血糖、胰岛敏感性的影响。
方法选取2020年7月—2022年6月福建医科大学附属龙岩第一医院收治的70例T2MD患者，按随机数表法分为联用组（n=35）与单用组（n=35）。
单用组给予二甲双胍，联用组给予达格列净联合二甲双胍，比较两组疗效。
结果治疗后，联用组空腹血糖、糖化血红蛋白餐后2 h血糖、胰岛素抵抗指数、丙二醛、终末氧化蛋白产物水平低于单用组，胰岛素分泌指数、胰岛素敏感性指数、总抗氧化能力、超氧化物歧化酶、过氧化氢酶水平高于单用组，差异有统计学意义（P均<0.05）。
结论达格列净联合二甲双胍治疗可有效调节T2MD患者糖代谢，增强胰岛敏感性，减轻胰岛素抵抗状况，控制血糖水平，明显改善机体氧化-抗氧化平衡。
[关键词] 2型糖尿病；达格列净；二甲双胍；血糖；胰岛敏感性[中图分类号] R9 [文献标识码] A [文章编号] 1672-4062（2024）01（a）-0061-04Effect of Dapagliflozin Combined with Metformin Treatment on Blood Glucose and Islet Sensitivity in Type 2 Diabetes Mellitus PatientsZHENG Tingting1, CHEN Lishen2, RAO Zhihui1, LIN Meiling11.Department of Pharmacy, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, 364000 China;2.Department of Pharmacy, Fuzhou Second Hospital Affiliated to Xiamen University, Fuzhou, Fujian Province, 350007 China[Abstract] Objective To investigate the effects of dapagliflozin combined with metformin treatment on blood glucose and islet sensitivity in patients with type 2 diabetes mellitus (T2MD). Methods 70 T2MD patients admitted to Long⁃yan First Hospital Affiliated to Fujian Medical University from July 2020 to June 2022 were selected and divided into the combination group (n=35) and the monotherapy group (n=35) by random number table method. Metformin was given to the monotherapy group and dapagliflozin combined with metformin was given to the combination group to com⁃pare the efficacy of the two groups. Results After treatment, the levels of glucose, glycasylated hemoglobin, 2-hour plasma glucose, homeostatic model assessment-insulin resistance, malondialdehyde, and advanced oxidation protein product were lower in the combination group than those in the monotherapy group, and the levels of homeostasis model assessment-insulin sensitivity, homeostasis model assessment-β, total-antoxidant capability, superoxide dis⁃mutase, and catalase were higher than those in the monotherapy group, and the differences were statistically signifi⁃cant (all P<0.05).Conclusion Dapagliflozin combined with metformin treatment can effectively regulate glucose me⁃tabolism in T2MD patients, enhance islet sensitivity, reduce insulin resistance status, control blood glucose levels, and significantly improve the oxidation-antioxidant balance of the body.[作者简介]郑婷婷（1983-），女，本科，主管药师，研究方向为医院药学。
TMA-DPH-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Mar.-25-2019Print Date:Mar.-25-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :TMA-DPHCatalog No. :HY-D0986CAS No. :115534-33-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C28H31NO3SMolecular Weight:461.62CAS No. :115534-33-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: -20°C, protect from lightShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
科玛嘉显色培养基在念珠菌鉴定中的应用价值探讨
科玛嘉显色培养基在念珠菌鉴定中的应用价值探讨影像与检验CHINAFOREIGNMEDICAL墨固科玛嘉显色培养基在念珠菌鉴定中的应用价值探讨黄峰秦淑国边其侠(安徽省宿州市皖北煤电集团总医院检验科安徽宿州234000)【摘要】目的评价科玛嘉显色培养基在念珠茵鏊定中的应用价值.方法用法国生物梅里埃公司生产的ATBID32C鉴定卡和科玛嘉显色培养基同时鉴定190株念珠茵.结果190株念珠茼中,科玛嘉显色培养基鉴定出白色念球菌127株,光滑念珠茵35株,热带念珠茵21株,克柔念珠茵2株.ID32C鉴定卡鉴定出白色念珠茵127株,光滑念珠茵36株,热带念珠茵22株,克柔念珠茵2株.结论科玛嘉显色培养基在念珠茵鉴定中符合率高,方法简便,用时较短且价格便宜,能快速准确地整定出临床常见念珠茵.ID32C鉴定卡能将念球菌全部鉴定到种,但价格较贵,且用时较长.【关键词l科玛嘉显色培养基念珠茵【中图分类号】R37【文献标识码】A【文章编号】1674--0742(2009)02(b)--0149--02 近年来由于高效广谱抗生素,肾上腺皮质激素,免疫抑制剂,恶性肿瘤化疗及放疗,多种侵袭性操作手段的广泛应用,导致菌群失调的真菌感染日益增多,因此及时准确的培养及鉴定出念珠菌,成为了微生物室急需要解决的重要问题.科玛嘉显色培养基是通过培养基上产生颜色差异和菌落特征来进行快速鉴定念珠菌的培养基,我们将此培养基与ATBexpression自动细菌鉴定/药敏系统的配套ATBID32C鉴定卡作了如下对比.1材料与方法1.1标本我院门诊与住院患者真菌培养标本1356份.1.2培养基和试剂沙保罗培养基(SDA)干粉购自杭州天和微生物试剂有限公司,科玛嘉显色培养基干粉购自郑州博赛生物技术研究所.ATBID32C鉴定卡为法国生物梅里埃公司产品.1.3仪器法国梅里埃ATBexpression自动细菌鉴定/药敏系统;30~C孵育箱.1.4方法表1190酵母样真菌分类结果名称标本直颈分泌物痰p段尿其他合计(%)将SDA~N科玛嘉显色培养基按常规制成培养基,各类标本按常规同时分区划线接种于SDA培养基和科玛嘉显色培养基,30~C培养24～4gh后观察结果,在两种培养基上7d不生长判为阴性.(1)在SDA培养基上培养阳性者经革兰染色确认为酵母样菌后,严格按生物梅里埃ATBID32C的鉴定系统操作,24～48h后用ATBexpression自动细菌鉴定/药敏系统测定结果.(2)在科玛嘉显色培养基上生长为翠绿色菌落(直径约2ram)为白色念珠菌,蓝灰色菌落(直径约1.5mm)为热带念珠菌,紫红色边缘模糊有微毛(直径约4～5mm)为克柔念珠菌,整个菌落紫红色(直径约2ram)为光滑念珠菌,白色为其他念珠菌.2结果(1)1356份标本在SDA上培养出190株酵母菌,在SDA上用A TBID32C鉴定卡鉴定分类结果见表1,在科玛嘉显色培养基上鉴定分类结果见表2.(2)190株科玛嘉显色培养基可鉴定株为185株,占总株数的97.4%,而ATBID32C与科玛嘉显色培养基直接鉴定法鉴定符合率为98.4%.3讨论(1)本文的检测结果表明,白色念珠菌占酵母样真菌数量的66.8‰光滑念珠菌占18.4%,热带念珠菌占l1.1%,克柔念珠菌占1.1%,这4种念珠菌占总数的97.4%,由此可以看出,本地区的念珠菌感染还是以白色念珠菌为主,但是光滑念珠菌感染已经上升到第2位,热带念珠菌感染所占的比例有所下降.(2)由于科玛嘉显色培养基对于不同酵母菌菌落显现不同颜色及形态差别,据此可对常见四种念珠菌作出初步判断,对于白色念珠菌,光滑念珠菌,热带念珠菌,克柔念珠菌与ATBID32C鉴定符合率达到了98.4%,差异无显着性(,0.05),表明这与许宏涛报道的结果接近….(3)在实际工作中,我们发现,科玛嘉显色培养基能在24～72h鉴定出4种常见的念珠菌,尤其是白色念珠菌,克柔念珠菌,他们的颜色和菌落特征明显,能够快速准确地得到鉴定(24-48h),而光滑念珠菌,热带念珠菌有时则需要更长一点的时间,使菌落颜色得到充分的表现,才能得到准确的判断(48～72h).A TBID32C法鉴定的结果很准确,但其价格较高,且分离培养需要24-48h,接种ID32C鉴定板条后需再培养24-48h,方能得出结果,所需时间相对较长,并且需要配套的仪器,而应用科玛嘉显色培养基不仅缩短了检测时间,而且价袼适CHINAFOREIGNMEDICALTREA TMENT中罗医疗149影像与检验高密度脂蛋白胆固醇的直接测定法研究谢智光(广西中医学院附属瑞康医院检验科广西南宁530011)【摘要】目的建立高密度脂蛋白胆固醇直接测定法法.方法用甾类糖苷化合物与胆固醇醴酶和胆固醇氧化酶制备的高亲和性酶化合物,结合特殊表面活性刺,通过对测定条件的优化,实现HD1-_C的直接测定.结果本方法与磷鸪酸镁(PTA—Mg2+)沉淀法…和葡聚糖一氯化镁(DS50--Mg)~淀结合ALBK法口相关性良好,分别为,=0.990I,Y=1.0l6X-O.0818和,=0.9960.Y=1.008X一0.063.批内cV<1.B%,日问cV<2.1%,线性范围逸5.4mmol/L,回收率!oo±5%.TG浓度迭30mmol/L,抗坏血酸<3.5mmol/1,血缸蛋白<4.8g/L和胆红素<540mol/L时无显着干扰.当用纯的不同浓度的LDL加入准确定值的新鲜血清中,观察脂蛋白在血清中的反应.结果纯LDL—C浓度在10.Ommol/L以内对本法无显着干扰.结论本文建立的高密度脂蛋白胆固醇直接法方法,其性能指标符合临床使用要求.标本无需预处理,精密度好,准确性高,适用于各种自动生化分析仅.【关键词l高密度脂蛋白胆固醇直接测定法【中图分类号lR44【文献标识码lA【文章编号l1674--0742(2009)o2(b)一ol50-02 近年来流行病学及大规模临床研究已经证实高密度脂蛋白(HDL)对动脉血管壁有直接的保护作用,并能促进动脉粥样斑快的消退,甚至部分研究发现高密度脂蛋白胆固醇(HDL—c)较LDL—C能更好地预测冠心病的危险】.高密度脂蛋白胆固醇(HDL—C)的直接测定法有不需要血清标本预处理的优点,适于直接上自动生化分析仪检测,目前已为各大医院所采用,也是今后发展的趋势.我们采用甾类糖苷化合物与胆固醇酯酶和胆固醇氧化酶制备的高亲和性酶化合物,结合对高密度脂蛋白胆固醇具有较强作用的表面活性剂研制的直接测定HDL-C~/d的工作已获得成功,现报道如下.1材料与方法1.1仪器.罗氏全自动分析仪1.2试剂试剂I:缓冲液,高亲合酶胆固醇酯酶化合物,高亲合酶胆固醇氧化酶化合物,辣根过氧化物酶,抗坏血酸氧化酶,HDAOS,稳定剂和防腐剂;试剂II:缓冲液,4一氨基安替比林,表面活性剂,稳定剂和防腐剂.校准血清为:HBS抗原阴性,HCV和HIV阴性,无脂浊,黄疸,溶血的键康体检者的新鲜混合人血清,1mL分装冻干,然后用DS50一Mg法进行定值.1.3测定方法HITACHI7060型自动分析仪参数:反应类型:二点终点法;反应温度:3712;波长:(主)546/(次)700nml样品:3L,JJ~R1180"L,3～5min读取空白读数(A1),然后加R260L,5min后读取测定读数(A2).1.4比较方法磷钨酸镁(PTA—Mg)沉淀法和葡聚糖(DS50)-氯化镁沉淀法.2实验结果2.1特异性试验取新鲜混合血清对HDL—C进行定值,浓度为1.75mmol/L;将其分成9份,分别加入超速离心分离的LDL纯品组份,加入的LDL-C的量分别为1.2,2.4,3.6,4.8,6.0,7.2,8.4和9.4mmol/L,然后分别用本法测定上述9份样品的HDL-C值,经校准加入LDL组份的稀释因素,结果说明加入LDL—C达10.0mmol/L并不影响HDL—C的测定结果.2.2线性范围中,操作简便,适合我国大,中,小型实验室使用l2】.(4)对于混合念珠菌感染的判断,科玛嘉显色培养基显示了极大的优势,两种或多种念珠菌混合感染均可作出明确判断口l.(5)另外,我们在日常的念珠菌培养试验中发现,在科玛嘉显色培养基生长的念珠菌,将其用ATBID32C鉴定卡进行试验并不影响结果的确认,有关文献对此曾有报道NI.因此,有条件的医院可以采用科玛嘉显色培养基与仪器法结合的方法,真菌培养的标本可以直接接种科玛嘉显色培养基,这样可以快速,简便地分离鉴定出大部分临床常见的念珠菌,对于少数不能显色或显色不充分有疑问的菌株可以用仪器鉴定,这样既可以降低成本,又可以提高鉴定的准确性.参考文献【1】许宏涛,张秀珍.科玛嘉念珠菌显色培养基的应用【J】.中华检验医学杂志,2000,23(5):298～299.15O中岁医疗CHINAFOREIGNMEDICALTREATMENT【2]周广,谢元宏,王知秋.科玛嘉显色培养基与API鉴定念珠菌的分析比较【J】.Jll;lls医学院学报,2004,19(1).[3】周燕等.科玛嘉念珠菌显色培养基与沙保罗培养基的应用比较【J】.现代检验医学杂志,2005,5:54.【4】朱成宾,夏永祥,窦露.科玛嘉念珠菌显色培养基的临床应用与评价【J】.实用医技杂志,2003,10(6).【收稿日期】2008—11—12。
GeXP简介
•Alignment
•Call scores
•Heterozygote Detection
2013/11/12
6
GeXP荧光系统
•GeXP更适合检测突变/杂合子： •波长越长，干扰越少 ，背景噪音低;
•650nm •laser •750nm •laser
•无10％的cut off把噪音，不会把10％以上杂合子去掉；
•NO Interference •from biological materials
7
个体化用药检测
KIT-Exon9
PDGFRA-exon12
EGFR突变检测
肿瘤药物对应相关基因的检测
药物名称 易瑞沙/特罗凯类 检测基因
EGFR-Exon18 突变 EGFR-Exon19 突变 EGFR-Exon21 突变 EGFR-Exon20突变 C-KIT-Exon9 突变 C-KIT-Exon11 突变 C-KIT-Exon13 突变 C-KIT-Exon17 突变 PDGFRα-Exon12 PDGFRα-Exon18 CYP2D6*10 多态性 XRCC1-Exon6 多态性 XRCC1-Exon10 多态性 ERCC1-codon118 多态性 MRP2-Exon10 多态性 BRCA1-Exon2 (女)多态性 BRCA1-Exon20 (女)多态性 XPD基因多态性 UGT1A1 *6 多态性 UGT1A1*28 多态性 DPYD*2A 多态性
伊马替尼 他莫昔芬
铂类
伊立替康 氟脲嘧啶类
HBV分型、耐药突变检测
2、片段分析
• 只需要研究长度，不需要知道具体序列 • 分别率为1bp
片段分析应用
STR/SSR
融合基因，可变剪切体
化学工作者网站
化学工作者看过来，可以在线查找化学结构式！1./cgi-bin/hsrun/Distributed/HahtShop/HAHTShop.htx;start=HS_SearchCenter中，选择Search Structures，然后，就可以分别根据：Product Name 和CAS登录号，还有Molecular Formula进行查找。
在这里查到的化合物基本都有一些参数和它的结构式（Structure Image），然后将图片保存成Gif即可！当然，如果你只知道化合物的结构式，不知道叫什么，可以选择下面的Sub Structure Search ，然后 Step 1 Choose a Drawing tool. I want to Download Kekule (requires download of Kekv214.exe) Step 2 Install the plug-in you downloaded in step 1 Close this browser. Return to the directory where you saved the plug-in and double click on the file name given in step 1. Step 3 Return to this page and click the "Structure Search"button. 安装好软件即可将画好的图片粘贴上即可查找，非常方便，我用它查了一些结构式，给了我一大堆，呵呵，本人化学方面英语不是很好，一个个查看才找到，不过还好是宽带，呵呵：－）2./大家去这儿看看，查询非常简单3.【推荐】【原创】能查几万个化合物的NMR IR谱图的网址 [精华]4.能查几万个化合物的NMR IR谱图的网址 SDBS Integrated Spectral Data BaseSystem for Organic Compounds http://www.aist.go.jp/RIODB/SDBS/sdbs/owa/sdbs_sea.cre_frame_sea NIST WebBook /5.美国专利pdf全文下载的好地方 6.免费在线查合成路线/depts/chemistry/courses/toolkits/247/practice/m edialib/data/7.中科院上海有机化学研究所化学专业数据库http://202.127.145.134/tf123456/6543218.中科院上海有机化学研究所数据库（/lccdb/sjk.htm），免费注册使用，现在已经改版，性能提高许多。
门冬胰岛素联合二甲双胍对妊娠期糖尿病患者血糖控制效果及对新生儿结局的影响
DOI：10.16658/ki.1672-4062.2023.23.059门冬胰岛素联合二甲双胍对妊娠期糖尿病患者血糖控制效果及对新生儿结局的影响李福霞1，谢秋燕1，陈明21.福州台江医院妇产科，福建福州350004；2.福州台江医院检验科，福建福州350004[摘要]目的探讨门冬胰岛素联合二甲双胍对妊娠期糖尿病（gestaional diabetes mellitus， GDM）患者血糖控制及新生儿结局的影响。
方法回顾性分析2019年4月—2023年4月福州台江医院接诊的70例GDM患者的临床资料，依不同用药方案分为对照组和观察组，单纯门冬胰岛素治疗的35例作对照组，门冬胰岛素联合二甲双胍治疗的35例作观察组，比较两组血糖控制水平、新生儿结局、不良反应发生情况。
结果治疗后，观察组空腹血糖（fasting plasma glucose，FPG）、餐后2 h血葡萄糖（2-hour plasma glucose，2 hPG）为（4.75±0.61）、（6.26±0.81）mmol/L，低于对照组的（5.23±0.86）、（7.82±1.04）mmol/L，差异有统计学意义（t=2.693、7.000，P< 0.05）。
观察组巨大儿、胎儿窘迫发生率为2.86%，低于对照组的22.86%，差异有统计学意义（χ2=6.248，P<0.05）。
两组不良反应发生率对比，差异无统计学意义（P>0.05）。
结论门冬胰岛素联合二甲双胍治疗GDM的血糖控制效果理想，可降低新生儿不良结局的发生，具有较高的安全性。
[关键词] 门冬胰岛素；妊娠期糖尿病；血糖；新生儿结局；安全性[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062（2023）12（a）-0059-04Effect of Insulin Aspartate Combined with Metformin on Blood Glucose Control in Gestational Diabetes Mellitus and Neonatal OutcomesLI Fuxia1, XIE Qiuyan1, CHEN Ming21.Department of Obstetrics and Gynecology, Fuzhou Taijiang Hospital, Fuzhou, Fujian Province, 350004 China;2.De‐partment of Laboratory, Fuzhou Taijiang Hospital, Fuzhou, Fujian Province, 350004 China[Abstract] Objective To investigate the effects of insulin aspartate combined with metformin on blood glucose con‐trol and neonatal outcomes in patients with gestaional diabetes mellitus (GDM). Methods The clinical data of 70 GDM patients admitted to Fuzhou Taijiang Hospital from April 2019 to April 2023 were retrospectively analyzed, and they were divided into control group and observation group according to different medication regimen. The control group was 35 cases treated with insulin aspartate alone, and the observation group was 35 cases treated with insulin aspartate combined with metformin. Blood glucose control, neonatal outcomes and adverse reactions were compared between the two groups. Results After treatment, fasting blood glucose (FPG) and 2-hour plasma glucose (2 hPG) af‐ter meals were (4.75±0.61) mmol/L and (6.26±0.81) mmol/L in observation group, which were lower than (5.23±0.86) mmol/L and (7.82±1.04) mmol/L of control group, and the differences were statistically significant (t=2.693, 7.000, P< 0.05). The incidence of fetal distress in the observation group (2.86%), was lower than that in the control group (22.86%), and the difference was statistically significant (χ2=6.248, P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). Conclusion Insulin aspartate combined with metformin in the treatment of GDM has ideal blood glucose control effect, can reduce the occurrence of neonatal ad‐verse outcomes, and has a high safety.[作者简介]李福霞（1972-），女，本科，主治医师，主要从事妇产科临床研究工作。
益生菌对阿尔茨海默病作用的研究进展
益生菌对阿尔茨海默病作用的研究进展发布时间：2021-12-14T06:08:15.523Z 来源：《中国结合医学杂志》2021年12期作者：宋鑫萍1,2，李盛钰2，金清1[导读] 阿尔茨海默病已成为威胁全球老年人生命健康的主要疾病之一，患者数量逐年攀升，其护理的经济成本高，给全球经济造成重大挑战。
近年来研究显示，益生菌在适量使用时作为有益于宿主健康的微生物，在防治阿尔茨海默病方面具有积极影响，其作用机制可能通过调节肠道菌群，影响神经免疫系统，调控神经活性物质以及代谢产物，通过肠-脑轴影响该病发生和发展。
宋鑫萍1,2，李盛钰2，金清11.延边大学农学院，吉林延吉 1330022.吉林省农业科学院农产品加工研究所，吉林长春 130033摘要：阿尔茨海默病已成为威胁全球老年人生命健康的主要疾病之一，患者数量逐年攀升，其护理的经济成本高，给全球经济造成重大挑战。
近年来研究显示，益生菌在适量使用时作为有益于宿主健康的微生物，在防治阿尔茨海默病方面具有积极影响，其作用机制可能通过调节肠道菌群，影响神经免疫系统，调控神经活性物质以及代谢产物，通过肠-脑轴影响该病发生和发展。
本文综述了近几年来国内外益生菌对阿尔茨海默病的作用进展，以及其预防和治疗阿尔茨海默病的潜在作用机制。
关键词：益生菌；阿尔茨海默病；肠道菌群；机制Recent Progress in Research on Probiotics Effect on Alzheimer’s DiseaseSONG Xinping1,2，LI Shengyu2，JI Qing1*(1.College of Agricultural, Yanbian University, Yanji 133002，China)(2.Institute of Agro-food Technology, Jilin Academy of Agricultural Sciences, Chanchun 130033, China)Abstract：Alzheimer’s disease has become one of the major diseases threatening the life and health of the global elderly. The number of patients is increasing year by year, and the economic cost of nursing is high, which poses a major challenge to the global economy. In recent years, studies have shown that probiotics, as microorganisms beneficial to the health of the host, have a positive impact on the prevention and treatment of Alzheimer’s disease. Its mechanism may be through regulating intestinal flora, affecting the nervous immune system, regulating the neuroactive substances and metabolites, and affecting the occurrence and development of the disease through thegut- brain axis. This paper reviews the progress of probiotics on Alzheimer’s disease at home and abroad in recent years, as well as its potential mechanism of prevention and treatment.Key words：probiotics; Alzheimer’s disease; gut microbiota; mechanism阿尔茨海默病（Alzheimer’s disease, AD），系中枢神经系统退行性疾病，属于老年期痴呆常见类型，临床特征主要包括：记忆力减退、认知功能障碍、行为改变、焦虑和抑郁等。
化学仿制药参比制剂目录(第六十七批)
株式会社
未进口原研药品
67-22
普瑞巴林缓释片
Pregabalin Extended release Tablets/Lyrica Cr
165mg
Pf Prism CV/UPJOHN US 2 LLC
未进口原研药品
美国橙皮书
67-23
普瑞巴林缓释片
Pregabalin Extended release Tablets/Lyrica Cr
国际公认的同种药品
美国橙皮书
67-34
头孢地尼干混悬剂
Cefdinir for Oral Suspension
125mg/5mL
Aurobindo Pharma Limited
美国橙皮书
67-35
蔗糖铁注射液
Iron Sucrose Injection/Venofer
5ml:100mg铁和1.6g蔗糖
0.25%
（10ml:25mg）
Hospira Inc
未进口原研药品
美国橙皮书
67-27
左卡尼汀口服溶液
Levocarnitine Oral Solution/CARNITOR SF
10ml：1g
Leadiant Biosciences, Inc.
未进口原研药品
美国橙皮书
67-28
碳酸氢钠血滤置换液（钾4mmol/L）
Hemofiltration Replacement Fluid of Sodium Bicarbonate
（4mmol/L Potassium Calcium free）/PrismaSol
5000ml（250ml/4750ml）
BAXTER HEALTHCARE CORP
加拿大拟定肟菌酯的最大残留限量
加拿大拟定肟菌酯的最大残留限量
2008年5月20日，加拿大卫生部有害生物管理局（PMRA）拟定肟菌酯（Trifloxystrobin）最大残留限量。
目前，加拿大的最大残留限量是通过官方公报进行磋商后，根据食品药物法规(FDR)制定的。
通过Bill C-28对食品药物法的修订，预计于2008年生效，这将允许按照有害生物控制产品法合法的制定杀虫剂最大残留限量，而无须经过FDA所属法规的批准。
本文件的目的是对所列肟菌酯(Trifloxystrobin)，包括代谢物CGA-321113的MRLs进行咨询，这些限量是在PCPA于2008年6月28日生效后由PMRA拟定的。
咨询活动已经在Bill C-28生效之前开始，以便在FDA被修改后尽快合法的制定本文件所列的MRLs。
(注意：在将有关杀虫剂最大残留限量立法从食品药物法案过渡为有害生物控制产品法案(对拟定最大残留限量的磋商（PMRL2006-01))的文件中拟定的0.04ppm最大残留限量在G/SPS/N/CAN/276中通报）。
所列产品补充了作物14组核果的最大残留限量。
恶性肿瘤药物治疗相关不良事件健康状态负效用测量研究的系统评价
China Pharmacy 2022V ol.33No.14中国药房2022年第33卷第14期恶性肿瘤药物治疗相关不良事件健康状态负效用测量研究的系统评价Δ卢钰琼＊，代展菁，路云，常峰#（中国药科大学国际医药商学院，南京211198）中图分类号R 956文献标志码A 文章编号1001-0408（2022）14-1748-06DOI 10.6039/j.issn.1001-0408.2022.14.15摘要目的为我国开展健康状态负效用测量研究、计算药物经济学评价中的健康产出提供方法学参考。
方法计算机检索中国知网、万方数据、维普网3个中文数据库和PubMed 、Web of Science 、the Cochrane Library 3个英文数据库中有关恶性肿瘤药物治疗相关不良事件负效用测量的文献，检索时限均为各数据库建库起至2021年7月。
由2名研究者独立筛选文献并提取资料后进行定性分析，采用改良后的英国国家卫生与临床优化研究所决策技术支持文件进行质量评估，总结健康状态负效用测量的实践情况和存在问题并提出建议。
结果共纳入相关文献77篇。
首篇文献发表于1991年，之后发表数量呈波动式上升。
77篇文献共涉及120种不良事件，以效用研究（49篇，63.64％）为主，仅有3篇（3.90％）的调查国家/地区涉及中国。
35篇文献（45.45％）未说明研究设计类型；48篇（62.34％）未说明健康状态开发方法；52篇（67.53％）未说明健康状态验证方法；46篇（59.74％）设定并说明了基础健康状态；20篇（25.97％）进行了健康状态排名；应用的效用测量工具主要为标准博弈法和欧洲五维健康量表（各23篇，各占29.87％）；45篇（58.44％）的调研对象为患者人群；63篇（81.82％）未说明人群代表性检验；效用报告类型包括负值、非负值以及合并基础状态的非负值3种类型；45篇（58.44％）未说明效用统计方法。
德谷门冬双胰岛素注射液治疗2_型糖尿病临床效果及安全性探讨
DOI：10.16658/ki.1672-4062.2023.17.098德谷门冬双胰岛素注射液治疗2型糖尿病临床效果及安全性探讨林生，谢平，陈予福州市长乐区人民医院内分泌科，福建福州350200[摘要]目的研究德谷门冬双胰岛素注射液治疗2型糖尿病的临床效果及安全性。
方法选取于2022年7月—2023年4月福州市长乐区人民医院收治的2型糖尿病患者98例为研究对象，采用随机抓阄法分为两组，每组49例。
两组均联用常规降糖药物治疗，对照组采用甘精胰岛素注射液治疗，观察组采用德谷门冬双胰岛素注射液治疗。
对比两组临床治疗效果、临床症状好转时间和胰岛素用量情况、糖代谢指标、胰岛素功能指标、不良反应发生情况、心血管不良事件发生情况。
结果观察组总有效率高于对照组，差异有统计学意义（P<0.05）。
观察组尿酮体转阴时间、血糖达标时间、胰岛素用量均优于对照组，差异有统计学意义（P< 0.05）。
观察组空腹血糖、餐后2 h血糖、糖化血红蛋白均低于对照组，差异有统计学意义（P<0.05）。
观察组胰岛β细胞功能指数高于对照组，胰岛素抵抗指数、空腹胰岛素低于对照组，差异有统计学意义（P<0.05）。
两组恶心呕吐、倦怠乏力、低血糖总发生率比较，差异无统计学意义（P>0.05）。
两组心绞痛、心力衰竭总发生率比较，差异无统计学意义（P>0.05）。
结论德谷门冬双胰岛素注射液治疗2型糖尿病临床效果显著优于甘精胰岛素注射液，但是治疗安全性无显著变化。
[关键词] 2型糖尿病；德谷门冬双胰岛素注射液；不良反应；心血管不良事件[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）09（a）-0098-04Discussion on the Clinical Effect and Safety of Insulin Degludec and Insu⁃lin Aspart Injection in the Treatment of Type 2 Diabetes MellitusLIN Sheng, XIE Ping, CHEN YuDepartment of Endocrinology, Changle District People's Hospital, Fuzhou, Fujian Province, 350200 China[Abstract] Objective To study the clinical effect and safety of insulin degludec and insulin aspart injection in the treatment of type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes admitted to Fuzhou Changle District People's Hospital from July 2022 to April 2023 were selected as the study objects and divided into two groups with 49 cases in each group by random lottery method. Both groups were treated with conventional hypoglycemic drugs, the control group was treated with insulin glargine injection, and the observation group was treated with Degu asparton double insulin injection. The clinical therapeutic effect, time of improvement of clinical symptoms, insulin dosage, glucose metabolism index, insulin function index, occurrence of adverse reactions and cardiovascular adverse events were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The time of urine ketone body turning negative, blood glucose reaching standard and insulin dosage in observation group were better than those in control group, and the differences were statistically significant (P<0.05). Fasting plasma glucose, 2-hour postprandial blood glucose and glycated hemoglobin in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The function index of islet β cells in observation group was higher than that in control group, the insulin resistance index and fasting insulin was lower than that in control group, the dif⁃ference was statistically significant (P<0.05). There was no statistically significant difference in the total incidence of [作者简介]林生（1981-），男，本科，副主任医师，研究方向为糖尿病及其并发症的相关临床研究。
15523666_迷迭香酸对哮喘小鼠氧化性肺损伤的保护作用
$ 材 料 与 方 法
$C$ 材 料 !3!3!试验动物!0""8XDC[ 级雌性 &;B&&S 小鼠购自 广 西 医 科 大 学 实 验 动 物 中 心"动 物 合 格 证
号!D#2*%桂'"8!$?888"# 试 验 前 适 应 性 饲 养:P" 自由饮水 饮 食"饲 养 环 境 温 度 "$ c l! c"相 对 湿 度 $85 "085 # !3!3" 主 要 试 剂 和 药 品 9,D$D,'$1DZ?CQ 检测试 剂 盒 均 购 自 碧 云 天 生 物 技 术 研 究 所*,(; 购自 DEX\@ 公 司*液 态 铝 佐 剂 购 自 >OHM\I 公 司# 肿节风药材购自广 西 玉 林 中 桂 药 材 有 限 公 司"药 材
%!3广西大学动物科学技术学院"南宁 4:8884*"3广西畜牧研究所"南宁 4:888!'
摘要为评价迷迭香酸对哮 喘 小 鼠 模 型 氧 化 性 肺 损 伤 的 保 护 作 用"本 研 究 用 卵 清 蛋 白 %,(;'致 敏$激 发 雌 性 &;B&&S小鼠建立哮喘模型"并用 ,(; 和 Z"," 联合激发小鼠作为氧化肺损伤阳性对照模型#在最后一次滴鼻激 发 "$O 后 "取 支 气 管 肺 泡 灌 洗 液 %&;B['进 行 细 胞 计 数 并 测 定 活 性 氧 %9,D'$超 氧 化 物 歧 化 酶 %D,''和 谷 胱 甘 肽 过 氧化物酶%1DZ?CQ'水平"取左侧肺脏固定做 Z= 染色#结果显示"迷迭香酸可明显减少 &;B[ 中 细 胞 总 数 和 嗜 酸 性粒细胞数目"显著抑制肺组织和 &;B[ 中 9,D的产生"升高 D,' 和 1DZ?CQ水 平"改 善 肺 组 织 病 理 变 化# 本 试 验 结 果 表 明 "迷 迭 香 酸 对 氧 化 肺 损 伤 起 到 明 显 的 保 护 作 用 # 关 键 词 迷 迭 香 酸 *哮 喘 *氧 化 性 肺 损 伤 *抗 氧 化 中 图 分 类 号 9"0434 文 献 标 识 码 ; 文 章 编 号 !+6!?6":+%"8!6'!"?:+48?8+